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Background: Amyotrophic Lateral Sclerosis (ALS) is a devastating progressive neurodegenerative disease. Disease
pathophysiology is complex and not yet fully understood, but is proposed to include the accumulation of
misfolded proteins, as aggregates are present in spinal cords from ALS patients and in ALS model organisms.
Increasing autophagy is hypothesized to be protective in ALS as it removes these aggregates. Rapamycin is
frequently used to increase autophagy, but is also a potent immune suppressor. To properly assess the role of
rapamycin-induced autophagy, the immune suppressive role of rapamycin should be negated.
Findings: Autophagy is increased in the spinal cord of ALS mice. Dietary supplementation of rapamycin increases
autophagy, but does not increase the survival of mutant SOD1 mice. To measure the effect of rapamycin in ALS
independent of immunosuppression, we tested the effect of rapamycin in ALS mice deficient of mature
lymphocytes. Our results show that rapamycin moderately increases the survival of these ALS mice deficient of
mature lymphocytes.
Conclusions: Rapamycin could suppress protective immune responses while enhancing protective autophagy
reactions during the ALS disease process. While these opposing effects can cancel each other out, the use of
immunodeficient mice allows segregation of effects. Our results indicate that maximal therapeutic benefit may be
achieved through the use of compounds that enhance autophagy without causing immune suppression.
Keywords: Autophagy, Rapamycin, Neurodegeneration, Amyotrophic lateral sclerosis, Motor neuron disease,
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Amyotrophic Lateral Sclerosis (ALS) is a devastating
progressive neurodegenerative disease, which primarily
involves the loss of motor neurons and denervation of
muscle fibers, resulting in muscle weakness and paraly-
sis. The disease has an annual incidence of 2.7 cases per
100,000 people in Europe [1] and most patients succumb
to the disease within 3 to 5 years after onset. On average
10% of all ALS cases are familial, of which 20% are
caused by mutations in the superoxide dismutase 1
(SOD1) gene. Based on these mutations, ALS rodent
models have been generated that predictably mimic the* Correspondence: Ludo.VandenBosch@vib-kuleuven.be
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reproduction in any medium, provided the orpatient disease process [2]. As disease progression is in-
distinguishable between familial and sporadic cases,
common disease mechanisms are expected. Two of these
mechanisms are aggregation [3] and the impaired clear-
ance of misfolded proteins [4].
A process to induce clearance of aggregated or
misfolded proteins is macroautophagy (further described
as autophagy). This is an intracellular clearance mechan-
ism to degrade long-lived proteins and organelles. Au-
tophagy is increased in cells expressing (mutant) ALS
genes in vitro [5], in the spinal cord of ALS mice [6-8]
and of ALS patients [9]. Increasing autophagy is benefi-
cial in neurodegenerative disease models, including
those for Alzheimer’s disease [10], Parkinson’s disease
[10], spinal cerebellar ataxia 3 [11], Huntington’s disease
[12] and frontotemporal lobar dementia [13]. Also in
ALS mice, genetically increasing autophagy in neurons
increases survival [14]. Pharmacologically, increasingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Autophagy is increased in ALS mouse spinal cord. Western blot analysis of age-matched spinal cords of non-transgenic (non-tg, n = 4)
and end stage SOD1G93A mice (n = 4) (A). Quantification of Western blot signal of LC3-II for non-transgenic and end stage SOD1G93A mice (B), mTOR
(C) and p-mTOR (D). **p < 0.01.
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beneficial results.
Rapamycin is frequently used to pharmacologically in-
crease autophagy by inhibiting the phosphorylation of
the mammalian target of rapamycin (mTOR) [15]. In
ALS mice, this drug has severely decreased survival [6]
or did not affect survival [16]. Rapamycin is additionally
used as a potent immunosuppressant as it inhibits the
activation of T-cells [17]. Interestingly, removal of ma-
ture lymphocytes or functional T-cells in ALS mice de-
creases survival [18,19] and thus rapamycin may be, in
part, detrimental in ALS due to its immunosuppressive
action. Dietary restriction experiments on ALS mice have
shown to increase autophagy and decrease ALS mouse
survival [20]. These studies may also be influenced byFigure 2 Rapamycin delivered in chow increases autophagy in the sp
p-mTOR in the spinal cords of RAG1−/− mice fed vehicle or rapamycin con
spinal cords of mice fed chow containing rapamycin for 3 months (n = 4) o
ATG5 (E) and beclin-1 (F). *p < 0.05, **p < 0.01.immunosuppression as dietary restriction also decreases
activation of mTOR [21].
To confirm whether autophagy is increased in
SOD1G93A mice, we performed Western blot analysis.
The lipid-bound form of microtubule-associated pro-
teins 1A/1B light chain (LC3-II) is increased in the
spinal cord of end stage SOD1G93A compared to age-
matched non-transgenic mice (Figure 1A & B). mTOR is
similarly expressed at end stage (Figure 1A & C) as is
the phosphorylation of this receptor (Figure 1A & D).
Next, we confirmed that dietary supplementation of
rapamycin increases autophagy. Increased levels of LC3-II
are detected in spinal cords of RAG1−/− mice treated with
rapamycin (Figure 2B). The expression of mTOR remained
constant (Figure 2C), although the phosphorylation ofinal cord of RAG1−/− mice. Western blot analysis of LC3-II, mTOR and
taining chow for 3 months (A). Quantification of the levels of LC3-II in
r vehicle chow (n = 4) (B). Quantification of mTOR (C), p-mTOR (D),
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Additional markers of autophagy, ATG5 and beclin-1, are
also increased by rapamycin (Figure 2E & F).
To assess the effect of increased autophagy in ALS, we
treated pre-symptomatic SOD1G93A mice with rapamycin.
Rapamycin does not affect disease onset (Figure 3B), dis-
ease duration (Figure 3C) or survival of SOD1G93A mice
compared to SOD1G93A mice fed vehicle diet (Figure 3D).
However, a potential protective effect of increased autoph-
agy by rapamycin in SOD1G93A mice may be masked by
the detrimental immunosuppressive effect of rapamycin
on lymphocytes in SOD1G93A mice. To circumvent this
effect of rapamycin, we crossbred RAG1−/− mice, which
are devoid of mature lymphocytes [22], with SOD1G93A
mice to assess the effect of rapamycin in the absence of
mature lymphocytes. Interestingly, when the immuno-
suppressive effect of rapamycin on lymphocytes cannot
be exerted (as is the case in RAG1−/− mice), rapamycin
significantly prolongs disease duration (Figure 3G) and
survival with 6.5 days (Figure 3H), while it does not
affect disease onset (Figure 3F). Despite that ALS mice
may consume less chow as they approach end stage, a
trend is shown for increased autophagy in the spinalFigure 3 Rapamycin does not affect survival of SOD1G93A mice, but in
SOD1G93A mice fed vehicle (n = 9) or rapamycin chow (n = 7) relative weigh
SOD1G93A mice fed vehicle (n = 7) or rapamycin chow (n = 12) relative weig
of SOD1G93A mice that were fed vehicle (152.6 ± 1.8 days, n = 17) or rapam
SOD1G93A mice fed with vehicle (148.6 ± 2.0 days, n = 23) or rapamycin cho
levels of LC3-II (I), mTOR (J), phosphorylated mTOR (p-mTOR) (K), p62 (L) a
or rapamycin-containing chow (n = 4 and n = 5 for the analysis of p62 andcords of RAG1−/− SOD1G93A mice on rapamycin-
containing chow (Figure 3I-L). Additionally, RAG1−/−
SOD1G93A mice fed rapamycin-containing chow have a
similar amount of neurons in the spinal cord at end
stage (Figure 3M), suggesting these mice did not be-
come end stage due to other reasons than neuronal loss.
The slight increase of survival of RAG1−/− SOD1G93A
mice fed rapamycin-containing chow implies that the
beneficial effect of increasing autophagy in SOD1G93A
mice may be masked by the immunosuppressive effect
of rapamycin in mice with mature lymphocytes. In line
with this hypothesis, a recent study that assessed the ef-
fect of rapamycin on ALS mice showed a decreased sur-
vival of more than 2 weeks [6]. This is comparable to
the size of the effect on survival detected by others after
removing mature lymphocytes from ALS mice [23]. In
our mice, the survival of vehicle treated SOD1G93A and
RAG1−/− SOD1G93A mice do not significantly differ (p =
0.20), although there is a trend that RAG1−/− SOD1G93A
mice live slightly shorter (4.0 days).
The dual effect of rapamycin (immunosuppression and
increased autophagy) is a contraindication to use this
drug for ALS patients and thus the development ofcreases survival of SOD1G93A mice lacking mature lymphocytes.
t (A), onset-free survival (B) and disease duration (C). RAG1−/−
ht (E), onset-free survival (F) and disease duration (G). Survival analysis
ycin chow (153.1 ± 2.5 days, n = 17) (D). Survival analysis of RAG−/−
w (155.1 ± 1.8 days, n = 19, p = 0.04) (H). Western blot analysis of the
nd NeuN (M) for end stage RAG1−/− SOD1G93A mice fed vehicle (n = 4)
NeuN). *p < 0.05, **p < 0.01.
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immunosuppression is essential. As removing T-cells
may be detrimental in ALS, RAG1−/− mice are useful to
assess the role of autophagy in different disease models,
such as in inclusion body myopathy [24], until specific
autophagy-inducing compounds become available.
In summary, a protective effect of increasing autoph-
agy is expected in ALS, but not yet been demonstrated
pharmacologically in vivo. We circumvented the nega-
tive effect of rapamycin on lymphocytes by removing
these cells from SOD1G93A mice and found a moderate
but significant effect on survival. This protective effect
seems to be due to increased autophagy and indica-




Mice overexpressing SOD1G93A and recombination acti-
vating gene 1 knockout (RAG1−/−) mice were purchased
from Jackson Laboratories (Bar Harbor, USA) and
maintained on a C57BL/6 background. Chow and water
were provided ad libitum and mice were housed in the
specific pathogen free facility of KU Leuven. A decrease
of 10% in body weight compared to their average be-
tween day 90 and 105 is considered as disease onset.
Mice no longer surviving were assessed as 0 g. End stage
is defined as the age when mice could no longer right
themselves from their back within 10 s and this is the
measurement of survival. For Figure 3A-E both RAG1+/−
SOD1G93A and RAG1+/+ SOD1G93A mice were used, as
their survival does not differ. All experiments were
performed with the approval of the Animal Ethical Com-
mittee of KU Leuven (P020/2010).
Diet preparation
Rapamycin (LC Labs) was encapsulated by Southwest
Research Institute (San Antonio, USA) with coating ma-
terial Eudragit S100 (Röhm Pharma) as described previ-
ously [25]. Encapsulated rapamycin was processed in
Purina 5LG6 mouse chow by TestDiet (London, UK) at
a concentration of 14 mg/kg food (2.33 mg of rapamycin
per kg body weight per day, assuming a body weight of
30 g and a daily consumption of 5 g per mouse).
Rapamycin or vehicle chow substituted the animal house
chow ad libitum from 60 days of age until end stage or
160 days.
Western blot
Samples were size-separated through denaturing sodium
dodecyl sulfate polyacrylamide gel electrophoresis. Pro-
tein was electro-transferred to a nitrocellulose mem-
brane in Tris–glycine–methanol buffer and processed
with the Supersignal ChemiLuminiscence detection kit(Pierce Biotechnology Inc.). The following antibodies
were used: anti LC3-II, anti mTOR, anti p-mTOR, anti
Beclin, anti ATG5 and anti p-62 (Cell Signalling).
Statistical analysis
The statistical analysis was performed with Graphpad
Prism (version 5.04) software. Unpaired 2-sided Stu-
dent’s t-tests were used to analyse differences between 2
groups and the Gehan-Breslow-Wilcoxon for survival
data. Significance is assumed for p ≤ 0.05. Values are
shown as mean ± standard error of the mean.
Abbreviations
ALS: Amyotrophic lateral sclerosis; ATG5: Autophagy protein 5;
LC3: Microtubule-associated proteins 1A/1B light chain; mTOR: Mammalian
target of rapamycin; p-mTOR: Phosphorylated form of the mammalian target
of rapamycin; NeuN: Neuronal nuclear antigen (Feminizing Locus on X-3);
SOD1: Superoxide dismutase 1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KAS, SS and JD performed the murine behavioural experiments. SH and ABA
performed the Western blot analysis. KAS, PVD, WR, AL and LVDB
participated in the design of the study. KAS and LVDB participated in
preparation of the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We thank Elizabeth Fernandez (University of Texas Health Science Center
Barshop, Institute for Longevity and Aging Studies) and Carrie Schultz (Land
O’ Lakes Purina Feed) for their help in obtaining the rapamycin and eudragit
diets. In addition, we thank Lawrence Van Helleputte and Nancy Florenty for
technical support. This work was supported by grants from the “Fund for
Scientific Research Flanders” (FWO-Vlaanderen), the University of Leuven (KU
Leuven), the European Community's Health Seventh Framework Programme
(FP7/2007-2013) under grant agreement number 259867 and the Belgian
Government (Interuniversity Attraction Poles, programme P7/16) of the
Belgian Federal Science Policy Office. PVD holds a clinical investigatorship of
FWO-Vlaanderen. WR is supported by the E. von Behring Chair for
Neuromuscular and Neurodegenerative Disorders.
Author details
1Laboratory of Neurobiology, Vesalius Research Center, VIB, Leuven, Belgium.
2Experimental Neurology (Department of Neurosciences), Leuven Research
Institute for Neuroscience and Disease (LIND), University of Leuven (KU
Leuven), Leuven, Belgium. 3Autoimmune Genetics Laboratory, VIB, Leuven,
Belgium. 4Department of Microbiology and Immunology, University of
Leuven (KU Leuven), Leuven, Belgium. 5Department of Neurology, University
Hospitals Leuven, Leuven, Belgium.
Received: 16 April 2013 Accepted: 4 September 2013
Published: 11 September 2013
References
1. Logroscino G, Traynor BJ, Hardiman O, Chio A, Mitchell D, Swingler RJ, Millul
A, Benn E, Beghi E: Incidence of amyotrophic lateral sclerosis in Europe.
J Neurol Neurosurg Psychiatry 2010, 81:385–390.
2. Julien JP, Kriz J: Transgenic mouse models of amyotrophic lateral
sclerosis. Biochim Biophys Acta 2006, 1762:1013–1024.
3. Ticozzi N, Ratti A, Silani V: Protein aggregation and defective RNA
metabolism as mechanisms for motor neuron damage. CNS Neurol Disord
Drug Targets 2010, 9:285–296.
4. Ido A, Fukuyama H, Urushitani M: Protein misdirection inside and outside
motor neurons in amyotrophic lateral sclerosis (ALS): a possible clue for
therapeutic strategies. Int J Mol Sci 2011, 12:6980–7003.
Staats et al. Molecular Neurodegeneration 2013, 8:31 Page 5 of 5
http://www.molecularneurodegeneration.com/content/8/1/315. Shen X, Ying H, Qiu Y, Park JS, Shyam R, Chi ZL, Iwata T, Yue BY: Processing
of optineurin in neuronal cells. J Biol Chem 2011, 286:3618–3629.
6. Miyakawa T, Maeda A, Yamazawa T, Hirose K, Kurosaki T, Iino M: Encoding
of Ca2+ signals by differential expression of IP3 receptor subtypes. EMBO
J 1999, 18:1303–1308.
7. Tian F, Morimoto N, Liu W, Ohta Y, Deguchi K, Miyazaki K, Abe K: In vivo
optical imaging of motor neuron autophagy in a mouse model of
amyotrophic lateral sclerosis. Autophagy 2011, 7:985–992.
8. Morimoto N, Nagai M, Ohta Y, Miyazaki K, Kurata T, Morimoto M, Murakami
T, Takehisa Y, Ikeda Y, Kamiya T, Abe K: Increased autophagy in transgenic
mice with a G93A mutant SOD1 gene. Brain Res 2007, 1167:112–117.
9. Sasaki S: Autophagy in spinal cord motor neurons in sporadic
amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2011, 70:349–359.
10. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A,
Wyss-Coray T, Masliah E: Beclin 1 gene transfer activates autophagy and
ameliorates the neurodegenerative pathology in alpha-synuclein models
of Parkinson’s and Lewy body diseases. J Neurosci 2009, 29:13578–13588.
11. Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC:
Autophagy induction reduces mutant ataxin-3 levels and toxicity in a
mouse model of spinocerebellar ataxia type 3. Brain 2010, 133:93–104.
12. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton
DF, Duden R, O’Kane CJ, Rubinsztein DC: Inhibition of mTOR induces
autophagy and reduces toxicity of polyglutamine expansions in fly and
mouse models of Huntington disease. Nat Genet 2004, 36:585–595.
13. Wang IF, Guo BS, Liu YC, Wu CC, Yang CH, Tsai KJ, Shen CK: Autophagy
activators rescue and alleviate pathogenesis of a mouse model with
proteinopathies of the TAR DNA-binding protein 43. Proc Natl Acad Sci
USA 2012, 109:15024–15029.
14. Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R, Martinez G, Cuervo
AM, Brown RH, Glimcher LH: XBP-1 deficiency in the nervous system
protects against amyotrophic lateral sclerosis by increasing autophagy.
Genes Dev 2009, 23:2294–2306.
15. Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the
immunosuppressant rapamycin in yeast. Science 1991, 253:905–909.
16. Bhattacharya A, Bokov A, Muller FL, Jernigan AL, Maslin K, Diaz V, Richardson
A, Van Remmen H: Dietary restriction but not rapamycin extends disease
onset and survival of the H46R/H48Q mouse model of ALS. Neurobiol
Aging 2012, 33:1829–1832.
17. Thomson AW, Turnquist HR, Raimondi G: Immunoregulatory functions of
mTOR inhibition. Nat Rev Immunol 2009, 9:324–337.
18. Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH
Jr, Carroll MC: T lymphocytes potentiate endogenous neuroprotective
inflammation in a mouse model of ALS. Proc Natl Acad Sci USA 2008,
105:17913–17918.
19. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH: CD4+ T cells support glial
neuroprotection, slow disease progression, and modify glial morphology
in an animal model of inherited ALS. Proc Natl Acad Sci USA 2008,
105:15558–15563.
20. Patel BP, Hamadeh MJ: Nutritional and exercise-based interventions in
the treatment of amyotrophic lateral sclerosis. Clin Nutr 2009, 28:604–617.
21. Speakman JR, Mitchell SE: Caloric restriction. Mol Aspects Med 2011, 32:159–221.
22. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou
VE: RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992,
68:869–877.
23. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH:
Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral
sclerosis in mice and correlate with disease progression in patients with
amyotrophic lateral sclerosis. Brain 2011, 134:1293–1314.
24. Ching JK, Elizabeth SV, Ju JS, Lusk C, Pittman SK, Weihl CC: mTOR
dysfunction contributes to vacuolar pathology and weakness in valosin-
containing protein associated inclusion body myopathy. Hum Mol Genet
2013, 22:1167–1179.
25. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL,
Wilkinson JE, Frenkel K, Carter CS, et al: Rapamycin fed late in life extends
lifespan in genetically heterogeneous mice. Nature 2009, 460:392–395.
doi:10.1186/1750-1326-8-31
Cite this article as: Staats et al.: Rapamycin increases survival in ALS
mice lacking mature lymphocytes. Molecular Neurodegeneration 2013 8:31.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
